Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 2Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Multiple Myeloma 449Neoplasms, Plasma Cell 69Recurrence 42Immunoglobulin Light-chain Amyloidosis 24Neoplasms 12Paraproteinemias 9Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Renal Insufficiency 8Amyloidosis 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Follicular 7Lymphoma 7Lymphoma, B-Cell, Marginal Zone 6Leukemia, Plasma Cell 6Leukemia, Myeloid, Acute 6Hematologic Diseases 6Waldenstrom Macroglobulinemia 5Lymphoma, Large-Cell, Immunoblastic 5Leukemia 5Burkitt Lymphoma 5Immunoproliferative Disorders 4Hodgkin Disease 4Blood Protein Disorders 4Plasmacytoma 3Peripheral Nervous System Diseases 3Neoplasms by Histologic Type 3

Interventions

sargramostim 2liposomal amphotericin B 2Voriconazole 2Therapeutics 2Polymerase Chain Reaction 2Itraconazole 2Flow Cytometry 2Amplified Fragment Length Polymorphism Analysis 2thymoglobulin 1aldesleukin 1Valacyclovir 1Stem Cell Transplantation 1Rituximab 1Ribavirin 1Radiotherapy 1Proteasome Inhibitors 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Pentetic Acid 1Palivizumab 1Monatide (IMS 3015) 1Minocycline 1Methylprednisolone 1Methotrexate 1Lithium Carbonate 1Lithium 1Lenalidomide 1Interleukin-12 Subunit p35 1Interferon-alpha 1Immunomodulating Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Wilms Tumor × Bortezomib × Plasma cell × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡